DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Ophthotec (NASDAQ: OPHT)

52.15 0.17 (0.33%)

Quote as of


company name or ticker

Recent Quotes

OPHT $52.15 0.33%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $52.15
Previous Close $51.98
Daily Range $51.51 - $52.87
52-Week Range $30.17 - $58.29
Market Cap $1.8B
P/E Ratio -17.62
Dividend (Yield) $0.00 (0.0%)
Volume 123,379
Average Daily Volume 265,685
Current FY EPS -$3.08

Sector

Industry

Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website: http://www.ophthotechinc.com/

News & Commentary

3 Little-Known Biotechs Working On Potential Blockbusters

These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.

AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog

3 Little-Known Stocks I'm Glad I Bought

Ophthotech Corp, Portola Pharmaceuticals Inc., and Insys Therapeutics Inc., have been top performers this past year.

2 Tiny Biotechs That Could Have Blockbuster Opportunity

Got risk tolerance? Check out these two small cap biotechs with huge potential.

Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog

Ophthotech's (OPHT) CEO Dr. David Guyer on Q4 2014 Results - Earnings Call Transcript

Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog

Can These Three BioTech Companies Make It Big?

Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog

Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog

Benzinga's Top Initiations

See More OPHT News...